title: Optimal therapy for pelvic recurrence after radical hysterectomy for early-stage cervical cancer.
abstract: Forty-eight patients with pelvic recurrence after radical hysterectomy were evaluated. The influence of location of pelvic recurrence (sidewall versus central), histological grade, histological type, and interval from hysterectomy to recurrence had no influence upon curability by radiotherapy. Ten of twenty-eight patients treated by primary radiation therapy for recurrent disease remain without evidence of disease a minimum of 12 months post-therapy, with a projected 5-year disease-free survival in excess of 30%. No patient treated with adjuvant radiation after initial surgery was rendered disease free by subsequent treatment with radiotherapy. Eleven patients were explored for exenterative surgery. Three of six in whom exenteration was technically feasible remain alive without evidence of disease. None of 15 patients treated with chemotherapy remain free of disease. Radiation therapy remains the treatment of choice in post-radical hysterectomy recurrences confined to the pelvis. As exenterative therapy will result in the cure of a small number of patients with disease confined to the pelvis, exenteration should be considered in patients treated previously by radiotherapy. If these efforts fail, chemotherapy is unlikely to result in cure.
authors.affiliation: University of Alabama, Birmingham 35294.
authors.forename: M E
authors.initials: ME
authors.lastname: Potter
authors.forename: R D
authors.initials: RD
authors.lastname: Alvarez
authors.forename: F L
authors.initials: FL
authors.lastname: Gay
authors.forename: H M
authors.initials: HM
authors.lastname: Shingleton
authors.forename: S J
authors.initials: SJ
authors.lastname: Soong
authors.forename: K D
authors.initials: KD
authors.lastname: Hatch
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007044:Hysterectomy; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D009367:Neoplasm Staging; D010386:Pelvic Neoplasms / Q000628:therapy*; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*